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Abstract
Pneumocystis jirovecii is an important opportunistic infection in HIV-infected patients. In the
developed world, P. jirovecii epidemiology is marked by frequent colonization in
immunosuppressed patients, but data on the prevalence of colonization is very limited in sub-
Saharan Africa, where the majority of persons living with HIV reside. Our objective was to
describe the epidemiology of P. jirovecii colonization among HIV-positive patients in a cross-
sectional, hospital-based study of patients admitted with suspected pneumonia in Kampala,
Uganda. P. jirovecii was detectable in bronchoalveolar lavage fluid from 7 of 124 (6%)
consecutive patients with non-Pneumocystis pneumonia. Colonization was not associated with
patient demographic or clinical information. This prevalence is substantially lower than in
published studies in the developed world, and suggests that there is a limited reservoir of
organisms for clinical infections in this Ugandan population. These findings may partially explain
the low incidence of Pneumocystis pneumonia in Uganda and other sub-Saharan African
countries.
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Introduction
The detection of Pneumocystis jirovecii in the respiratory tract of patients without clinical or
microscopic Pneumocystis pneumonia (PcP) represents colonization. Although its clinical
significance is unclear, an improved understanding of Pneumocystis colonization can
provide insight into the epidemiology of PcP in high-risk groups, including the temporal and
geographic acquisition of organisms and the environmental reservoirs of P. jirovecii. In
humans, the prevalence of Pneumocystis colonization varies between patient groups, but is
most strongly associated with immunosuppression and may correlate with susceptibility to
clinical PcP.
The epidemiology and burden of P. jirovecii infection is heterogeneous in developing
countries with high prevalences of HIV such as those in sub-Saharan Africa. Serologic
investigations indicate that exposure to P. jirovecii is common in South Africa, Cameroon,
and the Gambia, and P. jirovecii is a significant cause of pneumonia and death in HIV-
infected infants in southern Africa. In adults, the prevalence of PcP amongst HIV-infected
patients with pneumonia has been reported between 5% and 39%, but these may be
underestimates owing to the difficulty of microscopic diagnosis in these resource-limited
settings. The widespread exposure to P. jirovecii early in life but relatively low incidence of
infection in high-risk adults could be explained by either a limited reservoir for P. jirovecii
transmission in adults or the acquisition of protection from clinical diseases in adults.
The epidemiology of P. jirovecii colonization in high-risk HIV-infected patients in sub-
Saharan Africa is largely unknown. One study reported a prevalence of 9%, although it
enrolled only outpatients and relied upon detection of Pneumocystis in induced sputa, which
is less sensitive than bronchoscopy. Because colonized patients serve as a reservoir for
transmission, improved understanding of this phenomenon may inform estimates of the
burden of clinical disease due to P. jirovecii. Herein, we endeavor to describe the
epidemiology of P. jirovecii colonization among hospitalized, HIV-infected Ugandans with
suspected pneumonia by applying a sensitive molecular assay to detect P. jirovecii DNA in
bronchoalveolar lavage (BAL) specimens collected in a cross-sectional study of HIV-
infected patients hospitalized with non-Pneumocystis pneumonia at Mulago Hospital, a
national referral center in Kampala, Uganda.
Materials and Methods
Ethics statement
The study was approved by institutional review boards at Mulago Hospital and Makerere
University, the University of California, San Francisco, the University of North Carolina at
Chapel Hill, and by the Uganda National Council for Science and Technology.
Enrollment and data collection
Consecutive patients admitted to Mulago Hospital were screened for inclusion between
September 2007 and October 2008. Patients were enrolled if they had cough ≥ 2 weeks but
< 6 months, were HIV-infected, had received a clinical diagnosis of pneumonia, and
provided informed consent. Clinical and demographic information were collected on
standardized forms.
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All patients had a chest x-ray performed and two sputum samples examined for acid-fast
bacilli (AFB) by direct Ziehl-Neelsen microscopy; those with sputa negative for AFB were
referred for bronchoscopy with BAL. Two experienced pulmonologists performed
bronchoscopies, which included complete visualization of central airways and BAL with up
to 125mL of sterile normal saline lavaged into the lobe of the lung most affected on chest x-
ray.
BAL specimens were examined by trained laboratory technicians in the Microbiology
Department at Mulago Hospital and, for mycobacterial testing, the National Tuberculosis
Reference Laboratory. Analyses included AFB smear and Lowenstein-Jensen culture for M.
tuberculosis, smear and culture for fungi, and modified Giemsa stain for P. jirovecii. In
addition, Giemsa-stained BAL specimens were re-reviewed for P. jirovecii by a masked,
independent reader at San Francisco General Hospital. Aliquots of 1–2mL of unprocessed
BAL fluid were frozen at −20°C for subsequent molecular analyses.
Molecular analyses
PCR testing was performed at the University of North Carolina by personnel masked to
clinical and microscopic diagnoses. BAL specimens were thawed and briefly vortexed.
Genomic DNA (gDNA) was extracted from 200uL of each BAL specimen using the EZ1
Virus Mini Kit v2.0 (Qiagen, Valencia, CA). Individual samples were amplified in a nested
PCR assay that targets the P. jirovecii mitochondrial large subunit of ribosomal DNA
(mtLSUrRNA) using a standard protocol. Products were electrophoresed on 1% agarose
gels. Separate work areas for gDNA extraction, reaction set- up, and electrophoresis were
maintained to minimize contamination of the PCR testing, and all reaction plates included
negative and positive controls with either molecular-grade water or gDNA from a patient
with known PcP, respectively.
Samples demonstrating amplification were purified with the QIAquick Gel Extraction Kit
(Qiagen). Purified amplicons were bi-directionally sequenced at the UNC Core Sequencing
Facility using the ABI PRISM BigDye Version 1.1 Terminator Cycle Sequencing Ready
Reaction Kit with AmpliTaqR DNA Polymerase (Applied Biosystems, Foster City, CA).
Sequences were analyzed with Sequencher v4.10 (Gene Codes, Ann Arbor, MI) after
alignment with the reference mtLSUrRNA sequence M58605.1, and genotypes were
assigned according to standard nomenclature.
Definitions and statistical analyses
These analyses included patients with a negative modified Giemsa smear for PcP, originally
read at Mulago Hospital and confirmed as negative at San Francisco General Hospital. P.
jirovecii colonization was defined as the presence of P. jirovecii DNA, as determined by the
amplification of the mtLSUrRNA target, in a PcP-negative patient. Final diagnoses were
determined based on microbiologic results and clinical response. Bacterial pneumonia was
assigned as a final diagnosis in the event of improvement with empiric antimicrobial therapy
without a confirmed microbiologic diagnosis. Final diagnosis was categorized as “unknown”
when the patient died prior to completing the diagnostic evaluation or when the evaluation
was negative and any response to empiric therapy was unable to be assessed because the
patient was lost to follow-up. Post-discharge vital status was assessed either in person or by
telephone two months after discharge. Antiretrovirals were not routinely begun during
hospitalization or at discharge; their initiation after discharge was at the treating clinician’s
discretion, but generally would not have been done within 2 months after discharge.
All data were analyzed using Stata/IC (version 10, Stata Corp, College Station, TX). For the
cross-sectional data, we calculated means, medians, and proportions of clinical predictors in
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patients with and without colonization, and assessed bivariate associations by using Fisher’s
exact or the Kruskal-Wallis test for categorical or continuous variables, respectively. Using
the two-month follow-up data, we calculated a risk-ratio for death either prior to or after
discharge. A two-tailed p<0.05 was considered significant for all analyses.
Results
Of 130 patients who underwent bronchoscopy, 124 had negative modified Giemsa stains and
were thus PcP-negative. Median age was 33 years (interquartile range 28 – 39 years) and
57% were women. Final diagnoses in these PCP-negative patients were tuberculosis (30%),
bacterial pneumonia (24%), multiple diagnoses (23%), and unknown (23%). Among the 30
patients with multiple pulmonary diagnoses, the most common diagnoses were
Cryptococcus neoformans (14), pulmonary tuberculosis (11), and pulmonary Kaposi’s
sarcoma (9), each in conjunction with other diagnoses. HIV was a new diagnosis for 31
patients (25%). Of the 93 patients with known HIV infection at admission, 77 (83%)
reported taking PcP prophylaxis with trimethoprim-sulfamethoxazole or dapsone. Of all 124
patients, 34 patients (27%) died either prior to discharge or within two months of discharge.
Specimens from 7 of 124 patients (6%) were positive in the mtLSUrRNA assay, indicating
colonization with P. jirovecii. All positive and negative controls returned expected results.
There were no significant differences in clinical presenting factors between colonized and
non-colonized patients (Table 1). Notably, among the 31 patients for whom HIV was a new
diagnosis upon admission, 2 (7%) were colonized. At 2-month follow-up, 71% (5/7)
colonized patients had died, compared with 25% (29/117) of non-colonized patients (Risk
Ratio 2.9; 95% confidence interval 1.6 – 5.1).
All seven colonized patients had CD4 cell counts below 200 cells/mm3 (range 7 – 171). Five
patients were diagnosed with pulmonary tuberculosis (with or without a secondary
diagnosis), one had pulmonary Kaposi’s sarcoma, and in one patient the diagnosis was
unknown. Five of seven patients had known HIV infection upon admission, all of whom
reported taking PcP prophylaxis with cotrimoxazole prior to presentation. Genotyping of the
mtLSUrRNA amplicons demonstrated genotype 1 in four patients and genotype 3 in six
patients (three patients had both genotypes present concurrently).
Discussion
In this population of HIV-infected patients with non-Pneumocystis pneumonia admitted to a
referral hospital in Kampala, Uganda, only 6% of patients were colonized with P. jirovecii.
Although this may reflect the frequent receipt of PcP prophylaxis (83%) among the patients
with known HIV, even among the 31 patients in whom HIV was newly diagnosed only 7%
were colonized. Additionally, although the low colonization prevalence precluded a full
analysis, colonized patients were almost three times as likely to die within two months after
discharge. Because colonized individuals may serve as reservoirs for P. jirovecii
transmission, the low prevalence of colonization in these high-risk patients suggests that in
Uganda, in comparison with other settings, transmission of P. jirovecii is limited. (Kyeyune,
den Boon et al. 2010)
The overall prevalence of colonization in our cohort of HIV-infected patients is substantially
lower than in other settings. Majorities of similar patients hospitalized with non-
Pneumocystis pneumonia in San Francisco (69%) and New Orleans (68%) were colonized
when tested with the same molecular assay. When using a similar assay, 46% of HIV-
infected men dying of non-Pneumocystis respiratory illnesses were colonized, although this
varied between US cities from 16% to 70%, suggesting geographic differences in the
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prevalence of P. jirovecii colonization. Study design differences may contribute to the
variation between studies, but we believe our study accurately reflects the epidemiology of
P. jirovecii colonization in Kampala owing to the enrollment of consecutive patients with
clear inclusion criteria and the employment of a high standard of diagnostic and
microbiologic testing.
Several factors may account for this low prevalence. Use of PcP prophylaxis was common
in this cohort, though this has not been associated with reduced colonization in other studies.
Moreover, colonization was similarly infrequent in patients without a prior diagnosis of
HIV, who were therefore not using PcP prophylaxis. Though we did not collect data on pre-
admission antimicrobial use, most (98%) patients presented with fever, and given the
common use of sulfadoxine-pyrimethamine for presumptive antimalarial fever treatment in
Uganda, many patients may have received incidental therapy for PcP with this medication
prior to presentation. Finally, the low prevalence may be the result of complex local
ecological and host factors which have produced diverse rates of colonization in other
locales. Given the emerging correlation between the local prevalence of colonization and the
local incidence of disease, understanding the factors accounting for the epidemiology of
colonization may inform understanding of clinical disease.
The low prevalence of colonization in the high-risk patients that we investigated supports
the hypothesis that PcP results from human-to-human spread of P. jirovecii and not the
reactivation of latent infection. Similar to populations in Europe and the United States, early
life exposure to P. jirovecii is common in African populations. Given these data, incident
PcP that resulted from reactivation would likely require prevalent colonization, particularly
in patients that were heavily immunosuppressed and thus at high risk for PcP. That high-risk
patients are infrequently colonized with P. jirovecii suggests that incident PcP in these
patients more likely results from interpersonal spread. Furthermore, infrequent carriage in
highly-immunosuppressed individuals also suggests that the population reservoir of latent
organism for transmission is very limited. Taken together, these observations may account
for the observed low incidence of PcP in HIV-infected patients in sub-Saharan Africa (van
Oosterhout, Laufer et al. 2007; Kyeyune, den Boon et al. 2010) compared with Europe and
the US.
Two other findings merit attention. First, we observed only two different mtLSUrRNA
genotypes in the colonized patients, and three of seven patients had mixed genotypes.
mtLSUrRNA genotypes have not been associated with disease severity and are more useful
as a tool to better understand the epidemiology of P. jirovecii. The small number of isolates
precludes significant conclusions, and the absence of genotypes 2 and 4 may simply result
from chance.
Second, despite comparable degrees of immunosuppression, spectra of diagnoses, and
patient demographics, a significantly greater proportion of P. jirovecii-colonized than non-
colonized patients died soon after discharge. We believe that these patients were colonized
and not infected because 1) the results of the Giemsa-stained slides of BAL were
independently confirmed by a second technologist, and 2) a low organism count is suggested
by negative results on both modified Giemsa staining and in PCR assays targeting both the
single-copy P. jirovecii dihydropteroate synthase (dhps) and dihydrofolate reductase (dhfr)
genes (Huang, Taylor et al. 2010). However, we cannot exclude the possibility that these
colonized patients subsequently developed PcP and died from this disease. Nevertheless, the
limited number of colonized patients precludes a comprehensive multivariate analysis of risk
factors for death, and this preliminary bivariate association should be explored in future
studies before any causal relationship is inferred.
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Our study has several limitations. Though the nested PCR assay we used is considered
highly sensitive for P. jirovecii, more intensive specimen collection may increase yield
(Ponce, Gallo et al. 2010). Nevertheless, the use of this assay enables comparison with other
studies from different settings that have documented much higher prevalences of
colonization. The high frequency of reported use of PcP prophylaxis among those with
known HIV infection may have decreased the prevalence of colonization. Nevertheless, as
noted, prevalence was also low among those not taking prophylaxis. Finally, though we note
a bivariate association between colonization and death after admission, a comprehensive
analysis of risk factors for death is impossible given the limited number of colonized
patients, as above.
In this cross-sectional study of HIV-infected patients in Kampala with pneumonia that
employed aggressive diagnostic measures, the prevalence of P. jirovecii colonization was
low. Our study informs the understanding of the epidemiology of P. jirovecii in HIV-
infected patients in Uganda, where HIV infection is prevalent. Further studies utilizing less-
invasive oropharyngeal and sputum specimens and molecular testing can characterize
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Table 1
Characteristics of colonized and non-colonized patients
Colonized
Total (n=124) Yes (n=7) No (n=117) p-valuea
Presenting characteristics
Age, years, median (IQR) 33 (28 – 39) 38 (27 – 44) 32 (28 – 38) 0.57
Women, % (no.) 57 (71) 57 (4) 57 (67) 1.0
Final diagnosisb, % (no.)
 Tuberculosis 30 (37) 43 (3) 29 (34)
 Bacterial pneumonia 23 (29) 0 25 (29) 0.36
 Multiple diagnoses 24 (30) 43 (3) 23 (27)
 Unknown 23 (28) 14 (1) 23 (27)
New diagnosis of HIV, % (no.) 25 (31) 29 (2) 25 (29) 1.0
Known HIV, % (no.) 75 (93) 71 (5) 75 (88) 1.0
CD4 cells/mm3, median (IQR) 88 (22 – 196) 58 (9 – 124) 91 (23 – 211) 0.48
PcP prophylaxis on admissionc, % (no.) 83 (77) 100 (5) 82 (72) 0.58
ARVs on admissionc, % (no.) 24 (22) 20 (1) 21 (24) 1
Outcome
Died within 2 months following discharge, % (no.) 27 (34) 71 (5) 25 (29) 0.016
HIV: human immunodeficiency virus. ARV: antiretroviral
a
Determined using Fisher’s exact or the Kruskal-Wallis test.
b
Tuberculosis includes pulmonary, extrapulmonary, culture-negative, and culture-positive.
Multiple diagnoses includes those listed as well as Cryptococcus neoformans. Final diagnosis was categorized as “unknown” when the patient died
prior to completing the diagnostic evaluation or when the evaluation was negative and any response to empiric therapy was unable to be assessed
because the patient was lost to follow-up.
c
Among 93 patients with known HIV infection.
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